OBJECTIVE: To determine clinical and immunological correlates of high dose chemotherapy (HDC) + autologous stem cell transplantation (ASCT) in patients with severe rheumatoid arthritis (RA), refractory to conventional treatment. METHODS: Serial samples of peripheral blood and synovial tissue were obtained from seven patients with RA treated with HDC and autologous peripheral blood grafts enriched for CD34+ cells. Disease activity was assessed with the Disease Activity Score (DAS), serum concentrations of C reactive protein (CRP), and human immunoglobulin (HIg) scans, and the extent of immunoablation was determined by immunophenotyping of peripheral blood mononuclear cells, and immunohistochemistry and double immunofluorescence of synovium. RESULTS: Clinical responders (n = 5) had a larger number of cells at baseline expressing CD3, CD4, CD27, CD45RA, CD45RB, and CD45RO in synovium (p < 0.05), higher activity on HIg scans (p = 0.08), and a trend towards higher concentrations of CRP in serum than non-responders (n = 2). Subsequent remissions and relapses in responders paralleled reduction and re-expression, respectively, of T cell markers. A relatively increased expression of CD45RB and CD45RO on synovial CD3+ T cells was seen after HDC + ASCT. No correlations were found between DAS and changes in B cells or macrophage infiltration or synoviocytes. CONCLUSIONS: HDC + ASCT results in profound but incomplete immunoablation of both the memory and naïve T cell compartment, which is associated with longlasting clinical responses in most patients. The findings provide strong circumstantial evidence for a role of T cells in established RA, and demonstrate a role for the synovium in post-transplantation T cell reconstitution.
OBJECTIVE: To determine clinical and immunological correlates of high dose chemotherapy (HDC) + autologous stem cell transplantation (ASCT) in patients with severe rheumatoid arthritis (RA), refractory to conventional treatment. METHODS: Serial samples of peripheral blood and synovial tissue were obtained from seven patients with RA treated with HDC and autologous peripheral blood grafts enriched for CD34+ cells. Disease activity was assessed with the Disease Activity Score (DAS), serum concentrations of C reactive protein (CRP), and human immunoglobulin (HIg) scans, and the extent of immunoablation was determined by immunophenotyping of peripheral blood mononuclear cells, and immunohistochemistry and double immunofluorescence of synovium. RESULTS: Clinical responders (n = 5) had a larger number of cells at baseline expressing CD3, CD4, CD27, CD45RA, CD45RB, and CD45RO in synovium (p < 0.05), higher activity on HIg scans (p = 0.08), and a trend towards higher concentrations of CRP in serum than non-responders (n = 2). Subsequent remissions and relapses in responders paralleled reduction and re-expression, respectively, of T cell markers. A relatively increased expression of CD45RB and CD45RO on synovial CD3+ T cells was seen after HDC + ASCT. No correlations were found between DAS and changes in B cells or macrophage infiltration or synoviocytes. CONCLUSIONS: HDC + ASCT results in profound but incomplete immunoablation of both the memory and naïve T cell compartment, which is associated with longlasting clinical responses in most patients. The findings provide strong circumstantial evidence for a role of T cells in established RA, and demonstrate a role for the synovium in post-transplantation T cell reconstitution.
Authors: Sarah Bingham; Douglas Veale; Ursula Fearon; John D Isaacs; Gareth Morgan; Paul Emery; Dennis McGonagle; Richard Reece; Roy Clague; John A Snowden Journal: Arthritis Rheum Date: 2002-03
Authors: R J Verburg; A A Kruize; F H van den Hoogen; W E Fibbe; E J Petersen; F Preijers; J K Sont; R M Barge; J W Bijlsma; L B van de Putte; F C Breedveld; J M van Laar Journal: Arthritis Rheum Date: 2001-04
Authors: R K Burt; C Georganas; J Schroeder; A Traynor; J Stefka; F Schuening; F Graziano; S Mineishi; M Brush; M Fishman; C Welles; S Rosen; R Pope Journal: Arthritis Rheum Date: 1999-11
Authors: T Nanki; K Hayashida; H S El-Gabalawy; S Suson; K Shi; H J Girschick; S Yavuz; P E Lipsky Journal: J Immunol Date: 2000-12-01 Impact factor: 5.422
Authors: Eveline M Delemarre; Sarah T A Roord; Theo van den Broek; Evelien Zonneveld-Huijssoon; Wilco de Jager; Henk Rozemuller; Anton C Martens; Femke Broere; Nico M Wulffraat; Tibor T Glant; Berent J Prakken; Femke van Wijk Journal: Arthritis Rheumatol Date: 2014-02 Impact factor: 10.995